Pancreatic Cancer Research

ResearcherConsejo Superior de Investigaciones CientíficasActive in the last 2 years

Sonia Alcalá

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7644-4973; OpenAlex author ID A5020280669. Sources: OpenAlex.

Their work

Papers
24 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
91
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 6 papers · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 24

  1. A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-026-48584-2↗
  2. Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells. Co-author DOI 10.1186/s12929-026-01275-6↗
  3. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  4. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  5. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
  6. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis. Co-author DOI 10.1186/s12951-024-03010-5↗
  7. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
  8. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Co-author DOI 10.1186/s13046-023-02883-y↗
  9. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  10. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Co-author DOI 10.1186/s13046-021-02153-9↗
  11. Inhibition of Mitochondrial Dynamics Preferentially Targets Pancreatic Cancer Cells with Enhanced Tumorigenic and Invasive Potential. Co-author DOI 10.3390/cancers13040698↗
  12. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Co-author DOI 10.1038/s41467-020-16395-2↗
  13. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. First author DOI 10.1038/s41467-020-18954-z↗
  14. Induction of Lysosome Membrane Permeabilization as a Therapeutic Strategy to Target Pancreatic Cancer Stem Cells. First author DOI 10.3390/cancers12071790↗
  15. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/ijms21207437↗
  16. Correction: Alcalá, S., et al. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int. J. Mol. Sci. 2020, 21, 7437. Co-author DOI 10.3390/ijms21239215↗
  17. Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. First author DOI 10.4252/wjsc.v12.i11.1410↗
  18. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Co-author DOI 10.1038/s41388-019-0803-9↗
  19. The Anthrax Toxin Receptor 1 (ANTXR1) Is Enriched in Pancreatic Cancer Stem Cells Derived from Primary Tumor Cultures. Co-author DOI 10.1155/2019/1378639↗
  20. The Ever-Evolving Concept of the Cancer Stem Cell in Pancreatic Cancer. Co-author DOI 10.3390/cancers10020033↗
  21. The ever-changing landscape of pancreatic cancer stem cells. First author DOI 10.1016/j.pan.2016.04.004↗
  22. DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster. First author DOI 10.1158/0008-5472.can-15-3268↗
  23. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. First author DOI 10.1136/gutjnl-2014-308935↗
  24. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Co-author DOI 10.1016/j.stem.2011.10.001↗

Closest collaborators

The 25 strongest of 91 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bruno Sáinz · 23 shared papers, 2015–2026 · strength 2.89
  2. Christopher Heeschen · 12 shared papers, 2011–2024 · strength 1.25
  3. Juan Carlos López-Gil · 7 shared papers, 2020–2026 · strength 1.06
  4. Patrick Christian Hermann · 10 shared papers, 2011–2026 · strength 1.04
  5. Patricia Sancho · 9 shared papers, 2015–2026 · strength 1.04
  6. Julie Earl · 5 shared papers, 2019–2026 · strength 0.64
  7. Sandra Valle · 6 shared papers, 2018–2023 · strength 0.58
  8. Alfredo Carrato · 4 shared papers, 2019–2024 · strength 0.43
  9. Paola Martinelli · 4 shared papers, 2019–2023 · strength 0.41
  10. Marta Alonso‐Nocelo · 4 shared papers, 2018–2023 · strength 0.39
  11. Kıvanç Görgülü · 3 shared papers, 2021–2025 · strength 0.37
  12. Hana Algül · 3 shared papers, 2021–2025 · strength 0.37
  13. Carmen E. Guerra · 2 shared papers, 2024–2026 · strength 0.35
  14. Beatriz Parejo-Alonso · 2 shared papers, 2021–2026 · strength 0.33
  15. Kanishka Tiwary · 2 shared papers, 2020–2026 · strength 0.32
  16. Karolin Walter · 2 shared papers, 2020–2026 · strength 0.32
  17. Adrián Palencia‐Campos · 2 shared papers, 2024 · strength 0.32
  18. Thomas Theodor Werner Seufferlein · 2 shared papers, 2019–2026 · strength 0.31
  19. Claudio Luchini · 2 shared papers, 2021–2026 · strength 0.30
  20. Petra Jagušt · 2 shared papers, 2020–2021 · strength 0.27
  21. Jiaoyu Ai · 2 shared papers, 2021–2025 · strength 0.25
  22. Marina Lesina · 2 shared papers, 2021–2025 · strength 0.25
  23. Roland Michael Schmid · 2 shared papers, 2021–2025 · strength 0.25
  24. Dietrich Alexander Ruess · 2 shared papers, 2021–2025 · strength 0.25
  25. İhsan Ekin Demir · 2 shared papers, 2021–2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.